268 related articles for article (PubMed ID: 3168696)
1. Critical examination of therapeutic efficacy of a pH-sensitive enteric-coated pancreatic enzyme preparation in treatment of exocrine pancreatic insufficiency secondary to cystic fibrosis.
Dutta SK; Hubbard VS; Appler M
Dig Dis Sci; 1988 Oct; 33(10):1237-44. PubMed ID: 3168696
[TBL] [Abstract][Full Text] [Related]
2. Comparative evaluation of the therapeutic efficacy of a pH-sensitive enteric coated pancreatic enzyme preparation with conventional pancreatic enzyme therapy in the treatment of exocrine pancreatic insufficiency.
Dutta SK; Rubin J; Harvey J
Gastroenterology; 1983 Mar; 84(3):476-82. PubMed ID: 6549746
[TBL] [Abstract][Full Text] [Related]
3. Use of pancreatic Schilling test to determine efficiency of pancreatic enzyme delivery in pancreatic insufficiency.
Brugge WR; Goldberg HJ; Burke CA; Depping BJ
Dig Dis Sci; 1988 Oct; 33(10):1226-32. PubMed ID: 3168695
[TBL] [Abstract][Full Text] [Related]
4. Comparison of gastrointestinal pH in cystic fibrosis and healthy subjects.
Youngberg CA; Berardi RR; Howatt WF; Hyneck ML; Amidon GL; Meyer JH; Dressman JB
Dig Dis Sci; 1987 May; 32(5):472-80. PubMed ID: 3646103
[TBL] [Abstract][Full Text] [Related]
5. The pH-sensitive enteric-coated pancreatic enzyme preparations: an evaluation of therapeutic efficacy in adult patients with pancreatic insufficiency.
Dutta SK; Tilley DK
J Clin Gastroenterol; 1983 Feb; 5(1):51-4. PubMed ID: 6551402
[No Abstract] [Full Text] [Related]
6. Duodenal instillation of pancreatin does not abolish steatorrhea in patients with pancreatic insufficiency.
Zerega J; Lerner S; Meyer JH
Dig Dis Sci; 1988 Oct; 33(10):1245-9. PubMed ID: 3168697
[TBL] [Abstract][Full Text] [Related]
7. Comparison between a standard pancreatic supplement and a high enzyme preparation in cystic fibrosis.
Morrison G; Morrison JM; Redmond AO; Byers CA; McCracken KJ; Dodge JA; Guilford SA; Bowden MW
Aliment Pharmacol Ther; 1992 Oct; 6(5):549-55. PubMed ID: 1420747
[TBL] [Abstract][Full Text] [Related]
8. Comparison of effectiveness of pancreatic enzyme preparations in cystic fibrosis.
Mischler EH; Parrell S; Farrell PM; Odell GB
Am J Dis Child; 1982 Dec; 136(12):1060-3. PubMed ID: 7148760
[TBL] [Abstract][Full Text] [Related]
9. New modalities in the treatment of exocrine pancreatic insufficiency in cystic fibrosis.
Heijerman HG
Neth J Med; 1992 Oct; 41(3-4):105-9. PubMed ID: 1470278
[TBL] [Abstract][Full Text] [Related]
10. Controversies in the treatment of exocrine pancreatic insufficiency.
DiMagno EP
Dig Dis Sci; 1982 Jun; 27(6):481-4. PubMed ID: 6919479
[No Abstract] [Full Text] [Related]
11. Pancreatic enzyme pharmacotherapy.
Ferrone M; Raimondo M; Scolapio JS
Pharmacotherapy; 2007 Jun; 27(6):910-20. PubMed ID: 17542772
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacology for pediatricians. I. Pancreatic enzyme preparations, with special reference to enterically coated microspheres of pancrelipase.
Cho YW; Aviado DM
J Clin Pharmacol; 1981; 21(5-6):224-37. PubMed ID: 7021605
[No Abstract] [Full Text] [Related]
13. Efficacy and tolerability of a new formulation of pancrelipase delayed-release capsules in children aged 7 to 11 years with exocrine pancreatic insufficiency and cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled, two-period crossover, superiority study.
Graff GR; Maguiness K; McNamara J; Morton R; Boyd D; Beckmann K; Bennett D
Clin Ther; 2010 Jan; 32(1):89-103. PubMed ID: 20171415
[TBL] [Abstract][Full Text] [Related]
14. In vitro comparative study of three pancreatic enzyme preparations: dissolution profiles, active enzyme release and acid stability.
Aloulou A; Puccinelli D; Sarles J; Laugier R; Leblond Y; Carrière F
Aliment Pharmacol Ther; 2008 Feb; 27(3):283-92. PubMed ID: 17973644
[TBL] [Abstract][Full Text] [Related]
15. Fate of oral enzymes in pancreatic insufficiency.
Guarner L; Rodríguez R; Guarner F; Malagelada JR
Gut; 1993 May; 34(5):708-12. PubMed ID: 8504976
[TBL] [Abstract][Full Text] [Related]
16. An enteric-coated high-buffered pancrelipase reduces steatorrhea in patients with cystic fibrosis: a prospective, randomized study.
Brady MS; Garson JL; Krug SK; Kaul A; Rickard KA; Caffrey HH; Fineberg N; Balistreri WF; Stevens JC
J Am Diet Assoc; 2006 Aug; 106(8):1181-6. PubMed ID: 16863712
[TBL] [Abstract][Full Text] [Related]
17. Study of the gastrointestinal bioavailability of a pancreatic extract product (Zenpep) in chronic pancreatitis patients with exocrine pancreatic insufficiency.
Lieb JG; Patel D; Karnik N; Toskes PP
Pancreatology; 2020 Sep; 20(6):1092-1102. PubMed ID: 32800653
[TBL] [Abstract][Full Text] [Related]
18. [Comparative study of the effect of kreon and cotazyme forte in children with cystic fibrosis].
Zsíros J; Sólyom E
Orv Hetil; 1988 May; 129(19):995-9. PubMed ID: 3290773
[No Abstract] [Full Text] [Related]
19. Clinical pharmacology of pancreatic enzymes in patients with cystic fibrosis and in vitro performance of microencapsulated formulations.
Kraisinger M; Hochhaus G; Stecenko A; Bowser E; Hendeles L
J Clin Pharmacol; 1994 Feb; 34(2):158-66. PubMed ID: 8163716
[TBL] [Abstract][Full Text] [Related]
20. Comparative evaluation of a high lipase pancreatic enzyme preparation and a standard pancreatic supplement for treating exocrine pancreatic insufficiency in chronic pancreatitis.
Delhaye M; Meuris S; Gohimont AC; Buedts K; Cremer M
Eur J Gastroenterol Hepatol; 1996 Jul; 8(7):699-703. PubMed ID: 8853261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
